Drug
Binimetinib
Binimetinib: highest development phase Phase 1, developed by Novartis, Pierre Fabre. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis, Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| Binimetinib NCT02451865 | Phase 1 | Recurrent Non-Small Cell Lung Carcinoma |
| Binimetinib 15 MG NCT05810740 | Phase 1 | Melanoma |
Latest
No recent events.
Follow Binimetinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.